If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Lieutenant Governors (1919–1932) === Édouard Hesling (9 November 1919 – 7 August 1927) Robert Arnaud (7 August 1927 – 13 January 1928), acting Albéric Fournier (13 January 1928 – 22 December 1932) Gabriel Descemet (22 December 1932 – 31 December 1932)
== Development == C. brunneus are hemimetabolous. Females lay eggs over a 10-week period in the soil. Eggs hatch as early as April. Hatchlings typically go through four nymphal stages before becoming adults. Adults can live into the late autumn.
== Function in protein termination == Protein elongation continues until a stop codon appears on the mRNA. A Class I release factor (RF1 or RF2) binds to the stop codon, which induces hydrolysis of the tRNA-peptide bond in the P site, allowing the newly-formed protein to exit the ribosome. The nascent peptide continues to fold and leaves the 70S ribosome, the mRNA, the deacylated tRNA (P site), and the Class I release factor (A site). In a GTP-dependent manner, the subsequent recycling is catalyzed by a Class II release factor named RF3/prfC, Ribosome recycling factor (RRF), Initiation Factor 3 (IF3) and EF-G. The protein RF3 releases the Class I release factor so that it may occupy the ribosomal A site. EF-G hydrolyzes GTP and undergoes a large conformational change to push RF3 down the ribosome, which occurs alongside tRNA dissociation and promotes the ribosomal subunit rotation. This motion actively splits the B2a/B2b bridge, which connects the 30S and the 50S subunits, so that the ribosome can split. IF3 then isolates the 30S subunit to prevent re-association of the large and small subunits.
=== Procedure === Typically, PCR consists of a series of 20–40 repeated temperature changes, called thermal cycles, with each cycle commonly consisting of two or three discrete temperature steps (see figure below). The cycling is often preceded by a single temperature step at a very high temperature (>90 °C (194 °F)), and followed by one hold at the end for final product extension or brief storage. The temperatures used and the length of time they are applied in each cycle depend on a variety of parameters, including the enzyme used for DNA synthesis, the concentration of bivalent ions and dNTPs in the reaction, and the melting temperature (Tm) of the primers. The individual steps common to most PCR methods are: initialization, annealing and extension.
Sources: en.wikipedia.org
== Uses == Purified water is suitable for many applications, including autoclaves, hand-pieces, laboratory testing, laser cutting, and automotive use. Purification removes contaminants that may interfere with processes, or leave residues on evaporation. Although water is generally considered to be a good electrical conductor—for example, domestic electrical systems are considered particularly hazardous to people if they may be in contact with wet surfaces—pure water is a poor conductor. The conductivity of water is measured in Siemens per meter (S/m). Sea-water is typically 5 S/m, drinking water is typically in the range of 5-50 mS/m, while highly purified water can be as low as 5.5 μS/m (0.055 μS/cm), a ratio of about 1,000,000:1,000:1. Purified water is used in the pharmaceutical industry. Water of this grade is widely used as a raw material, ingredient, and solvent in the processing, formulation, and manufacture of pharmaceutical products, active pharmaceutical ingredients (APIs) and intermediates, compendial articles, and analytical reagents. The microbiological content of the water is of importance and the water must be regularly monitored and tested to show that it remains within microbiological control. Purified water is also used in the commercial beverage industry as the primary ingredient of any given trademarked bottling formula, in order to maintain critical consistency of taste, clarity, and color. This guarantees the consumer reliably safe and satisfying drinking.
=== Depositional environments === Dinosaur eggs are known from a variety of depositional environments. Beach sands: Beach sands were a good place for dinosaurs to lay their eggs because the sand would be effective at absorbing and holding enough heat to incubate the eggs. One ancient beach deposit in northeastern Spain actually preserves about 300,000 fossil dinosaur eggs. Floodplains: Dinosaurs often laid their eggs on ancient floodplains. The mudstones deposited at these sites are therefore excellent sources of dinosaur egg fossils. Sand dunes: Many dinosaur eggs have been recovered from sandstone deposits that formed in the ancient dune fields of what are now northern China and Mongolia. The presence of Oviraptor preserved in their life brooding position suggests that the eggs, nests, and parents may have been rapidly buried by sandstorms.
Nationalist movements in some countries and regions, notably Guatemala, Indonesia and Indochina, were often allied with Communist groups or otherwise perceived to be unfriendly to Western interests. In this context, the United States and the Soviet Union increasingly competed for influence by proxy in the Third World as decolonization gained momentum in the 1950s and early 1960s. Both sides were selling armaments to gain influence. The Kremlin saw continuing territorial losses by imperial powers as presaging the eventual victory of their ideology. The United States used the Central Intelligence Agency (CIA) to undermine neutral or hostile Third World governments and to support allied ones. In 1953, President Eisenhower implemented Operation Ajax, a covert coup operation to overthrow the Iranian prime minister, Mohammad Mosaddegh. The popularly elected Mosaddegh had been a Middle Eastern nemesis of Britain since nationalizing the British-owned Anglo-Iranian Oil Company in 1951. Winston Churchill told the United States that Mosaddegh was "increasingly turning towards Communist influence." The pro-Western shah, Mohammad Reza Pahlavi, assumed control as an autocratic monarch. The shah's policies included banning the communist Tudeh Party of Iran, and general suppression of political dissent by SAVAK, the shah's domestic security and intelligence agency. In Guatemala, a banana republic, the 1954 Guatemalan coup d'état ousted the left-wing President Jacobo Árbenz with material CIA support.
=== September === September 8, 2008: Latvia Latvia joins its northern neighbor Estonia in recession as GDP falls 0.2% in the second quarter from the first quarter, when it fell 0.3%. Property markets and construction have suffered in both Baltic states.
==== Progressive multiple sclerosis ==== In 2011, mitoxantrone was the first medication approved for secondary progressive MS. In this population, tentative evidence supports mitoxantrone moderately slowing the progression of the disease and decreasing rates of relapses over two years. In 2026, tolebrutinib, a BTK inhibitor, was approved for non-relapsing secondary MS in the EU. It reduces the activity of microglia, immune cells in the brain, as well as of B cells. New approved medications continue to emerge. In March 2017, the FDA approved ocrelizumab as a treatment for primary progressive MS in adults, the first drug to gain that approval. It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. According to a 2021 Cochrane review, ocrelizumab may reduce worsening of symptoms for primary progressive MS and probably increases unwanted effects but makes little or no difference to the number of serious unwanted effects. In 2019, siponimod and cladribine were approved in the United States for the treatment of secondary progressive multiple sclerosis (SPMS). Subsequently, ozanimod was approved in 2020, and ponesimod was approved in 2021, which were both approved for management of CIS, relapsing MS, and SPMS in the U.S., and RRMS in Europe. Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.